Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345377 | 0.95 | CYP2C19 (0.54) | CYP2C19HIF1AFFAR1CPT2TDP1 | |
| SCHEMBL6356323 | 0.92 | CYP2C19 (0.64) | CYP2C19HIF1AFFAR1CPT2TDP1 | |
| SCHEMBL6351858 | 0.90 | CYP2C19 (0.40) | CYP2C19HIF1ACNR2CYP1A2CYP2D6 | |
| SCHEMBL6345369 | 0.89 | CYP2C19 (0.57) | CYP2C19HIF1ACYP1A2CYP2D6 | |
| SCHEMBL6699596 | 0.89 | CYP2C19 (0.45) | CYP2C19HIF1AFFAR1CNR2CYP1A2 | |
| SCHEMBL6348374 | 0.89 | CYP2C19 (0.41) | CYP2C19HIF1ACNR2CYP1A2CYP2D6 | |
| SCHEMBL6344082 | 0.87 | CYP2C19 (0.66) | CYP2C19HIF1AFFAR1CPT2TDP1 | |
| SCHEMBL6354645 | 0.85 | CYP2C19 (0.46) | CYP2C19HIF1AFFAR1CNR2CYP1A2 | |
| SCHEMBL6354078 | 0.85 | CYP2C19 (0.49) | CYP2C19HIF1ACYP1A2CYP2D6 | |
| SCHEMBL6346489 | 0.84 | CYP2C19 (0.40) | CYP2C19HIF1ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703422-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISEASE, DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; DISORDER OF GLUCOSE METABOLISM; ALZHEIMER'S DISEASE; SYNDROME X; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ASSOCIATED DISORDER | ESPERION THERAPEUTICS, INC. | 2004-03-09 | — | — | US | claimed |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | CYP2C19 893/4885HIF1A 1092/4885FFAR1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.